Real-World Data Highlight Survival Benefit of Rituximab Maintenance After Frontline BR in MCL
Rituximab following first-line bendamustine demonstrated significant OS and EFS real-world benefits in mantle cell lymphoma.
Rituximab Maintenance Following BR in Frontline MCL: Real-World HighlightsRituximab maintenance following BR in the first line was associated with significantly improved median EFS and OS.Median EFS and OS improvements were associated with rituximab maintenance therapy among patients who achieved a CR with BR.No significant improvements with median EFS or OS data were shown for rituximab maintenance therapy for patients who achieved a PR with BR.
comments(0)
5-min edit window · permanent after that